Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | CCR1 | P32246 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | CCR8 | P51685 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8370881 | 0.81 | LMNA (0.50) | LMNACCR1CCR5CCR8KDM4E | |
| SCHEMBL27847333 | 0.75 | LMNA (0.46) | LMNACCR1CCR5CCR8KDM4E | |
| SCHEMBL6984529 | 0.74 | KDM4E (0.41) | LMNAKDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL6978190 | 0.73 | MEN1 (0.31) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL6986004 | 0.72 | PSMD14 (0.44) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| Phenanthroline SCHEMBL29354015 | 0.71 | CCR1 (1.00) | LMNACCR1CCR5CCR8KDM4E | |
| Phenanthroline SCHEMBL29367277 | 0.71 | CCR1 (1.00) | LMNACCR1CCR5CCR8KDM4E | |
| Phenanthroline SCHEMBL8845760 | 0.71 | CCR1 (1.00) | LMNACCR1CCR5CCR8KDM4E | |
| Phenanthroline SCHEMBL8312 | 0.71 | CCR1 (1.00) | LMNACCR1CCR5CCR8KDM4E | |
| SCHEMBL618332 | 0.69 | TDP2 (0.41) | MAPTSMN1; SMN2TDP1ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582241-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2011159553-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2017160670-A1 | M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-8530404-B2 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | LMNA 1545/4885CCR1 58/4885CCR5 41/4885 |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | LMNA 3859/4885CCR1 199/4885CCR5 303/4885 |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | TP53, MKI67, HDGF | LMNA 3372/4885CCR1 1012/4885CCR5 997/4885 |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | LMNA 3859/4885CCR1 199/4885CCR5 303/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | LMNA 1347/4885CCR1 574/4885CCR5 117/4885 |
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | LMNA 396/4885CCR1 245/4885CCR5 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.